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Introduction
Proper functioning of an arteriovenous fistula (AVF) is 
vital for hemodialysis treatment and is a significant con-
cern for kidney specialists and vascular surgeons. For pa-
tients with end stage renal disease (ESRD), an autologous 
fistula is the most suitable vascular access option. It has 
the lowest mortality rate compared to arteriovenous graft 
(AVG) and central venous catheter (CVC), and it has the 
lowest rate of re-intervention [1]. Due to these advantages, 
the National Kidney Foundation guidelines endorse the 
use of native AVF, which has a 65% primary success rate 
amongst patients about to commence hemodialysis [2]. 
According to Irish et al [3], vessel obstruction or im-
maturity accounts for 20% to 54% of cases with primary 
failure of AVF. Regional variations in practice patterns 
contribute to vascular access outcomes and patient 
morbidity and mortality. Considerable variation was 
observed in the practice patterns of hemodialysis ac-
cess operations. A study conducted by Dunn et al [4] 
found significant variation in practice patterns; general 
anesthesia use varied from 1.9% to 74.4%; preoperative 
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venous imaging by ultrasound or venogram varied from 
72.1% to 95.9%; native AVF vs. non-AVF varied from 58% 
to 85.1%; inadequate veins were cited in 68% of non-AVF 
cases, and the distribution of upper extremity AVF type 
across regions varied widely. Similarly, Asano et al [5] 
did not find meaningful relationships between AVF sur-
vival and various physician and staff practices. Final AVF 
failure rates were higher in facilities with higher median 
blood flow rates. They were also greater in North America 
and Europe/Australia/New Zealand than in Japan, but 
this difference was substantially attenuated after ac-
counting for regional differences in facility median blood 
flow rates. Fistula maturity is believed to be reduced by a 
number of demographic and clinical elements. Previous 
research indicated that a high rate of AVF maturation is 
influenced by lower body mass index (BMI), young age, 
male gender, and the absence of peripheral vascular dis-
ease (PVD) and diabetes [6,7]. 
Prognosis regarding the efficiency of a fistula is made 
with the help of duplex ultrasound, an instrument that 
enables evaluation of the success of fistula develop-
ment [8,9]. It might be possible to enhance vascular 
access results by constructing a more comprehensive 
picture of factors involved in the efficient development 
of fistulae. In addition, this will generate important data 
during pre-surgery evaluation that surgeons can use for 
decision-making. Independent predictive markers can 
be beneficial in anticipating the success rate of fistula de-
velopment without requiring invasive or expensive tests. 
Research studies conducted on the predictive markers 
of adequate and operative fistulae have failed to reach a 
consensus because they focused on different aspects and 
used different definitions of maturation, study design, 
clinical factors, and patient samples. Thus, surgeons are 
confronted with the challenge of classifying different risk 
factors and deciding which parameters to use to evalu-
ate the possibility of successful fistula development. The 
purpose of this literature review is to discuss the role of 
patient factors and blood markers in the development of 
AVF.
Factors associated with AVF maturation
Multiple factors are involved in the functional matura-
tion of AVFs, such as age, gender, and blood markers. Fig. 
1 shows factors associated with AVF maturation in pa-
tients with advanced renal failure.
Age 
It is possible that older people are at greater risk for dia-
betes and PVD. A meta-analysis of 13 cohort studies (of 
which 11 were retrospective) provides the best available 
evidence and shows that elderly individuals with radio-
cephalic AVF had a higher primary failure rate and de-
creased patency [10]. However, the definitions of “elderly” 
in the included studies ranged from 50 to 70 years, and 
the review was specific to wrist AVFs. 
Comparative studies on AVF patency in elderly and 
younger individuals have been conducted [11-13]. In 
particular, the effect of the intima-media width of radial 
arteries on early failure of radiocephalic AVF was studied 
using 90 individuals with ESRD who had undergone vas-
cular access surgery [13]. The surgery removed 10 mm of 
partial arterial wall using an elliptical type microscopic 
analysis, and a link among higher age, higher AVF matu-
ration failure, and intima-media width was revealed. The 
result of higher intima-media width is loss of vascular 
elasticity and vessel luminal narrowing, which cause a 
rise in arterial rigidity. Yan et al [14] showed that diabetes 
is a separate risk factor for intima-media width in pa-
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Figure 1. Factors affecting the maturation of arteriovenous fis-
tula (AVF).
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tients with kidney disease. 
Other studies, however, did not support worse AVF pa-
tency rates in patients. Lok et al [15] conducted a single-
center, retrospective analysis of over 440 AVFs. The study 
compared AVF results in different age groups to find that 
the construction of AVFs should not be affected by age. 
However, single center study results might have limited 
external generalizability. Other study results also show no 
relationship between primary AVF patency rates and age. 
Thus, the link between degree of AVF success and age is 
unclear, and no definite conclusions can be made [11,16]. 
Gender 
Research is now questioning the traditional belief that 
men have larger vessel diameters than women. In the 
Haemodialysis (HEMO) Study, female gender was identi-
fied as a significant predictor of AVG rather than AVF use 
[6], but there is little specific evidence for AVF patency 
differences between genders. A longitudinal study ex-
amined vascular access complications in a large cohort 
(n = 833) of hemodialysis patients who had permanent 
access in use one month after starting hemodialysis 
therapy and compared complications in men and women 
[17]. The study found that female gender was associated 
with a relative hazard of 1.58 (95% confidence interval 
[CI], 1.05-2.35) in AVF patients compared to male AVF 
patients. However, a retrospective study of over 190 indi-
viduals revealed variations in vasculature between men 
and women. Vessel diameters were calculated at 12 arte-
rial sites and 17 venous sites, revealing that no consider-
able variations exist in these diameters between genders. 
Furthermore, a meta-analysis indicated that one-year 
patency levels and maturation for radiocephalic AVFs are 
similar for men and women [18]. 
Coagulation factors 
AVF dysfunction remains a major contributor to the 
morbidity and mortality of patients on hemodialysis [19]. 
Failure of a newly created AVF to mature and develop-
ment of stenosis in an established AVF are two common 
clinical predicaments. The most common cause of ma-
ture AVF failure is stenosis of the venous segment, with 
20-40% of cases occurring within the first few centime-
ters of the vein distal (upstream) to the anastomosis, 
known as the “swing segment” [20]. A distal swing seg-
ment is the segment of the native vein that is mobilized 
during radialcephalic, brachial-cephalic, and transposed 
brachial-basilic fistula creation. A proximal swing seg-
ment occurs in the basilic vein near the axillary region 
during transposition surgery [21]. A naturally occurring 
swing segment occurs in the arch of the cephalic vein or 
cephalic arch segment as it drains into the axillary vein. 
This segment of the vein can experience turbulent flow 
and altered shear mechanical stress because it forms 
the outflow conduit for autogenous radial-cephalic and 
brachial-cephalic fistulas [22].
Chang et al [23] observed that infiltration by macro-
phages and lymphocytes in the vascular lining of an 
obstructed AVF caused considerably increased inflam-
matory activity. The endothelium plays a vital role in 
preventing thrombosis, regulating coagulation, and lipid 
transport [24]. Atherosclerosis can lead to disruptions in 
the vascular endothelium, enabling platelet accumula-
tion on the endothelium and initiating clotting. This can 
potentially degenerate into vessel obstruction [25]. When 
the endothelium deteriorates, endothelial cells produce 
and release a variety of substances, including plasmino-
gen-activator inhibitor-1, von Willebrand factor, throm-
boxane A2, fibrinogen, and tissue factor, which can be 
used as indicators of the degree of endothelial disruption 
[26,27]. 
A double blind randomized controlled study aimed to 
verify that ticlopidine is a successful and harmless way to 
decrease AVF early failure rates [28]. For one week prior 
to the procedure and for four weeks following it, medi-
cation (either placebo or ticlopidine) was administered 
to study participants. The findings revealed that 19% of 
study subjects given the placebo developed thrombosis, 
whereas only 12% of the study subjects given ticlopi-
dine developed thrombosis. However, the results did 
not reveal that ticlopidine had any noteworthy effect on 
preventing thrombosis following AVF procedures. Dem-
ber et al [29] carried out a randomized, double blind, 
and placebo-controlled trial in numerous centers in the 
United States, which focused on the effects of clopido-
grel administration in a sample of 877 patients with ad-
vanced chronic kidney disease (CKD) or ESRD who had 
just undergone surgery for fistula construction. Fistula 
thrombosis occurred in 53 (12.2%) participants assigned 
to clopidogrel and 84 (19.5%) participants assigned to 
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placebo (relative risk, 0.63; 95% CI, 0.46-0.97; P = 0.018). 
A systematic review was conducted to identify the in-
fluence of adjuvant drug therapy on fistula and graft pa-
tency rates in patients diagnosed with ESRD [30]. The re-
view included 10 randomized controlled trials using anti-
thrombotic drug treatment or anti-platelet drugs such 
as ticlodipine, aspirin, dipyridamole, and clopidogrel to 
prevent blockages in artery and vein access points for di-
alysis. Results showed that antiplatelet drugs, including 
ticlopidine, aspirin, and clopidogrel, had a positive influ-
ence. This indicates that the administration of antiplate-
let drugs to patients with AVF is feasible. However, most 
of the included trials had a short follow-up period, so the 
long-term benefits are not clear. Furthermore, long-term 
safety concerns of anti-platelet agents used for this pur-
pose are not clear.
Lipid profile 
The role of serum lipid profiles in AVF maturation is 
still largely unknown. Kirkpantur et al [31] conducted a 
retrospective three-year study on a group of 99 patients to 
analyze the connection between serum lipid profile and 
fistula thrombosis. Study results showed that serum lev-
els of cholesterol and triglycerides in patients with fistula 
thrombosis and those with functional fistulae were simi-
lar. Nonetheless, the former patients had considerably 
reduced high-density lipoprotein and albumin, as well 
as higher low-density lipoprotein and serum C-reactive 
protein levels than the latter group of patients. 
Features of classic uremic dyslipidemia include high 
levels of triglycerides, reduced high-density lipoprotein, 
and reduced overall concentration of cholesterol. Ad-
vanced kidney failure enhances these features, whereas 
renal replacement therapy and co-morbidities such as 
diabetes mellitus alter the features [32]. In association 
with CKD, atherosclerosis progresses more rapidly and 
manifests as extremely calcified plaques that adhere to 
the subintimal layers of the artery wall. In high concen-
trations, lipids interfere with mediators (angiotensin II, 
endothelin-1, plasminogen activator inhibitor-1, prosta-
cylin, and nitric oxide) that impact renal function [33]. A 
long-term case-control study in 60 patients with autolo-
gous AVF was carried out to analyze the effects of drugs 
or factors on AVF patency. Mean follow up time was 25 
months. The study results showed improved fistula pa-
tency (71.5% vs. 39.1%) at 2 years in patients taking folic 
acid and statins compared to those on no statin therapy 
[34]. In this small single center study, no significant dif-
ference was noted in high density lipoprotein, low den-
sity lipoprotein, triglycerides, or total cholesterol, except 
homocysteine (P < 0.01). 
Association of hypoalbuminemia with AVF outcome
In AVFs, thrombosis can also be caused by inflamma-
tion. Churchill et al [35] found that AVG obstruction was 
most frequently determined by hypoalbuminemia. Fur-
ther studies have revealed that, apart from being a sign of 
dietary deficiency in uremic patients, hypoalbuminemia 
is also a symptom of inflammation [36,37]. The indirect 
conclusion drawn from these results is that inflammation 
is involved in AVF thrombosis. 
The association between endothelial function and early 
stage progressive kidney disease has been investigated as 
a means of uncovering if clinically evident atherosclerotic 
vascular disease in CKD patients is linked to endothelial 
function abnormalities [38]. Endothelial cell dysfunction 
is often observed in individuals with impaired kidney 
function [39,40]. Plasma from patients with ESRD or ure-
mic toxins inhibits fundamental endothelial cell biologi-
cal processes such as viability, proliferation, migration, 
and wound healing [41,42]. Abnormalities in these endo-
thelial cell functions play a key role in vascular remodel-
ing, especially at the site of dialysis vascular access. AVFs 
require rapid proliferation of endothelial cells to restore 
the barrier, permeability, and biochemical regulatory 
functions of endothelial cells to control vascular repair, 
local thrombosis, inflammation, and neointimal hyper-
plasia [43]. Since uremia inhibits endothelial cell prolif-
eration and migration to eventually result in abnormal 
vascular remodeling, neointimal hyperplasia at the site of 
vascular access anastomosis is common. This results in 
primary access failure and ineffective dialysis [44]. 
Vein diameter 
Endothelial function is associated with arterial and ve-
nous remodeling, as determined by basic hemodynamic 
principles [45]. As more blood is delivered through the 
venous outflow limb of the AVF, wall shear stress, which is 
proportional to the amount of blood flow velocity and lu-
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men diameter, will rise. Theoretically, this should lead to 
venous dilation to normalize the shear stress. There is a 
high degree of correlation between the flow rate through 
an AVF and the venous diameter, indicating that flow is 
a primary determinant of final venous diameter [45,46]. 
It is likely that the magnitude of remodeling depends on 
hemodynamic stimuli, endothelium-derived mediators, 
and baseline stiffness of the vessels. 
Inadequate vessels used to construct AVFs are another 
cause of AVF failure. Allon and Robbin [47] have pro-
posed the use of pre-surgery ultrasound assessment to 
ensure that the chosen vessels can support the construc-
tion of an AVF. Khavanin et al [48] conducted a cross-
sectional study using a sample of 96 patients on hemodi-
alysis with native AVF to determine the relation between 
diameter and maturation of AVF. Study results found an 
association between vein diameter (mean vein diameter 
was 2.40 mm) and the success rate of fistula develop-
ment; however, a similar connection was not observed 
between fistula maturation and artery diameter (mean 
diameter of artery was 2.57 mm). Clinical examination 
and Doppler ultrasound measurements are the main-
stays of current preoperative assessment [49].
Diabetes 
The most preferred type of vascular access used for he-
modialysis is AVF [50,51]. Nevertheless, there has been 
an increase in the rate of AVF failure in the last three 
decades, caused by a growing number of elderly patients 
with CKD who also suffer from diabetes or vascular 
disease. As noted by Aronson et al [52], the changes in 
metabolism that accompany diabetes can manifest as 
pro-thrombotic situations, endothelial damage, deregu-
lated growth factors, and increased extracellular matrix 
deposition. Inflammation can participate in the initial 
development of AVF stenosis and thrombosis [21,53]. A 
retrospective study was performed on 31 patients with 
AVF to identify factors that can influence AVF remodeling 
[54]. The results indicated that diabetes is a significant 
negative predictor of venous remodeling. However, the 
sample size was small, and the significance of the find-
ings are questionable.
Endothelial dysfunction has been explained as imbal-
ance between the amount of vaso-dilatory and vaso-
constricting substances generated by the endothelium or 
between general endothelial activities [55]. Endothelial 
dysfunction can be a part of the mechanisms of a number 
of diseases, including diabetes mellitus, hypertension, or 
hypercholesterolemia. Endothelial dysfunction can also 
arise from environmental factors, such as exposure to air 
pollution and smoking tobacco products [56]. Endothe-
lium deregulation manifests as decreased production of 
nitric oxide, increased platelet aggregation, and antico-
agulant features [57]. All of these aspects play a role in the 
occurrence of vascular problems such as atherosclerosis 
in patients with diabetes. A key component of AVF matu-
ration is adequate dilation of the outflow vein. Changes 
in blood flow induce vascular remodeling, and the en-
dothelium controls the response to flow changes [58,59]. 
Upon damage to the vein during AVF construction, the 
endothelium is disturbed, impairing venous remodeling. 
Hypertension 
Risk factors such as cardiovascular disease, hyperlip-
idemia, and hypertension poorly predict AVF non-mat-
uration, prompting investigations into other risk factors 
such as hemodynamic profile or vessel morphology [60]. 
Endothelial function is impaired in hypertension, which 
decreases vascular relaxation and initiates inflammatory 
cell infiltration in blood vessels [61,62]. Macrophages and 
T cells represent basic pathologic features of the devel-
opment of atherosclerosis. From their initial location in 
elastic arteries in spaces that do not experience extreme 
shear stress, these features then propagate to the inner-
most membrane of smooth muscle cells, where they de-
posit connective tissues and initiate neovascularization 
[63]. 
Other studies, however, did not support hypertension 
as a major risk factor for AVF maturation [64,65]. A recent 
study by Kim et al [64] performed a single center cohort 
study (38 men and 12 women) to assess patient factors, 
vein diameter, and distensability of the radiocephalic 
vein at the wrist. Study analysis did not find any positive 
correlation between AVF maturation and patient factors 
of hypertension, diabetes, and gender. However, the sam-
ple size was not large enough to detect the effect between 
AVF maturation and hypertension. 
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Peripheral vascular disease 
The prevalence of PVD in people with diabetes is four 
times higher than in those without diabetes [66]. PVD 
develops gradually as a result of systemic atherosclerosis. 
Together with coronary artery disease and cerebrovascu-
lar disease, PVD represents one of the three main mani-
festations of atherothrombosis [67]. Atherothrombosis is 
a thrombus that develops atop a ruptured plaque situated 
at an afflicted part of the artery. Atherosclerotic plaques 
also form at vessel bifurcation points, possibly because 
of damaged protection mechanisms and disruptions in 
blood flow at these sites [68]. 
In the case of AVF used for hemodialysis access, vessel 
thrombosis represents the major factor that determines 
AVF failure. Chang et al [23] argued that vascular inflam-
mation can participate in this process, as it represents 
a significant symptom of vascular diseases. Ku et al [69] 
recruited 43 pre-dialysis patients awaiting AVF creation 
for the first time to compare the intima media thick-
ness of vessels among uremic patients, uncomplicated 
hypertensive patients, and healthy subjects using ul-
trasonographic measurements. Study findings reported 
that intima media thickness measurements during pre-
operative Doppler ultrasound imaging significantly cor-
related to histologic measures and, more importantly, to 
AVF thrombosis and inadequacy of an AVF to maintain 
dialysis at one year. Similarly, a single center cross sec-
tional study of 225 patients was conducted to evaluate 
the relationship between ankle-brachial pressure index 
(ABPI) < 0.9 and vascular access failure. Study findings 
showed that ABPI is a reliable marker for PVD and has a 
significant association with access failure after adjusting 
for other variables [70]. However, the study subjects were 
only from one regional hospital, and the study was obser-
vational. Therefore, it is susceptible to selection bias. 
Smoking 
Churchill et al [35] and Reilly et al [71] have analyzed 
the influence of smoking history on vascular access mor-
bidity but did not obtain any conclusive results. Wetzig et 
al [72] had shown earlier that smokers undergoing hemo-
dialysis exhibited an increased prevalence of early or late 
AVF failure. The discrepancies observed in the results 
could be because earlier peripheral vascular impairment 
in former and current smokers can trigger acute AVF 
obstruction. Ozdemir et al [73] examined the effects of 
smoking and blood eosinophil count on AVF maturation. 
This cross-sectional study included 141 patients with ad-
vanced renal failure. AVF thrombosis was detected in 60 
patients; in contrast, 81 patients had no thrombosis. The 
study findings strongly indicate that smoking in conjunc-
tion with a high amount of blood eosinophils can play a 
role in AVF failure. One limitation of the study was its ret-
rospective nature and it was limited to a single center. 
In addition, progression of atherosclerosis and ischemic 
nephropathy might play a role [74]. Endothelial dysfunc-
tion can be accompanied by other factors that increase 
the likelihood of developing atherosclerosis, including 
oxidized lipids, diabetes mellitus, and smoking [75,76]. 
Endothelial dysfunction generates a number of biologi-
cal effects that aid in the advancement of atherosclerosis, 
such as vasoregulation [77], enhanced blood coagulation 
[78], facilitation of penetration of inflammatory cells and 
lipids into the innermost wall layer [79], and enhance-
ment of the movement and multiplication of vascular 
smooth muscle cells [80]. 
Obesity 
The number of obese patients with ESRD who also are 
diagnosed with type 2 diabetes is constantly growing [81]. 
This group of patients is associated with a higher rate of 
AVF failure as they are predisposed to arteriosclerosis, 
and vessels in the forearm are more difficult to reach due 
to thick fat tissue [82]. This also increases the difficulty of 
performing phlebotomy on fistulae situated at a consid-
erable depth. Chan et al [32] carried out a retrospective 
cohort study on a group of 1,486 patients to analyze the 
connection between obesity and vascular access compli-
cations using BMI less than 30 kg/m2 as a reference for 
obesity. The study results found no connection between 
obesity and a higher rate of fistula failure; however, a re-
lationship between insufficient fistula development and 
high BMI was observed (odds ratio, 3.66; 95% CI, -1.27 
to 10.55, P = 0.017). Because this study represents fistula 
outcomes from a single dialysis center, the findings might 
not generalize to all dialysis centers. For example, in cen-
ters not using routine preoperative vascular mapping, the 
frequency of fistula placement might be lower in obese 
patients than in non-obese patients. 
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The prevalence of fistulae was lower in females, pa-
tients with PVD, black patients, obese patients, and 
older patients [6,83]. In obese patients, low rates of long-
term AVF preservation are usually caused by early vessel 
thrombosis, which is considered to degenerate from ad-
vanced myointimal hyperplasia, resulting in earlier vessel 
stenosis. This theory is corroborated by the connection 
between hyperinsulinemia, high levels of serum interleu-
kin 6, advanced myointimal hyperplasia, and increased 
incidence of vessel thrombosis in patients undergoing 
hemodialysis [84]. Interleukin 6 stimulates the produc-
tion of C-reactive protein, and high levels of C-reactive 
protein have been recorded in obese patients [85]. An-
other study revealed that C-reactive protein contributes 
to advancement of myointimal hyperplasia, which pro-
vides further evidence of the high rate of AVF failure in 
obese patients. 
Dialysis 
Late referral of patients initiating dialysis therapy with 
a temporary CVC can impair patency rate and fistula 
maturation. If a fistula is constructed after the patient 
has begun dialysis therapy, hemodialysis treatment can 
be extended with a temporary CVC. This can lead to the 
development of a number of complications, such as in-
sufficient blood flow, hematoma formation, recurrent 
thrombosis or failure, fibrosis, vessel wall damage, and 
bacteremia [86,87]. 
Previous studies examined complications related to 
CVC use before AVF construction and reported venous 
thrombosis rates as high as 58%, with a susceptibility 
for thrombosis in the cephalic and basilic veins [88,89]. 
Prospective observational study results have shown that 
temporary catheter use at the initiation of dialysis is 
linked to a higher risk of vascular access failure [90]. The 
authors hypothesized that AVF patency rates and matu-
ration are influenced by catheter utilization and related 
problems. This research used a substantial study sample 
of dialysis patients (n = 3,674) and involved an epidemio-
logical study that included over 300 institutions across 
Europe, America, and Japan. However, as pointed out by 
the authors, a causal link between cannulation and cath-
eter utilization and subsequent fistula failure cannot be 
made because the study was observational.
Conclusion
Successful vascular access provision is the foundation 
for successful hemodialysis. Determining the proper type 
of vascular access has prime significance for maximizing 
successful maturation of a fistula and avoiding surgical 
revision. Unfortunately, there are no consistent criteria 
that can be applied before creation of AVFs at present. 
The surgeon has to rely on clinical judgement and other 
investigatory parameters including a pre-operative du-
plex scan, which has a major role in determining the suc-
cess of fistula maturation. Although there is no consen-
sus, AVF selection (rather than AVG) is the recommended 
access for hemodialysis, as AVGs are 3.8 times more likely 
to require a thrombectomy and 3 times more likely to 
require access intervention than AVF. Further research 
studies are needed to determine how to predict, prevent, 
or treat failure of AVF maturation. 
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